The week in pharma: action, reaction and insight – week to November 7
By Barbara Obstoj-Cardwell
Research news last week featured US CRIPR genome-editing company Caribou Biosciences announcing positive early data on its Hodgkin lymphoma candidate vispacabtagene regedleucel (vispa-cell). US biotech start-up Braveheart Bio raised $185 million to support development of its cardiomyopathy candidate BHB-1893. Eli Lilly last week said it would move its obesity candidate eloralintide into Phase III following positive Phase II results. Lilly also inked a deal with the US government to reduce patient costs for obesity drugs including Zepbound and orforglipron.
Caribou Biosciences: much anticipated data readout
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze